Literature DB >> 8075585

Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL.

W D Ludwig1, A Reiter, H Löffler, D Hoelzer, H Riehm, E Thiel.   

Abstract

Immunophenotyping prospectively performed in about 2800 children and adults within the framework of the German multicentre ALL trials revealed marked differences in frequency distribution of immunologic subgroups with a higher incidence of immature B-cell precursor and pre-T/T phenotypic features in adults. Detailed immunophenotypic characterization by applying monoclonal antibodies to lymphoid- and myeloid-associated antigens as well as non-lineage-restricted molecules underlined the diagnostic value of pan-B and pan-T antigens that were expressed in virtually all cases of B-cell precursor (CD19, CD24) or T-cell ALL (cytoplasmic CD3, CD7) for lineage affiliation of leukemic blasts. About 10% of children and 20% of adults disclosed simultaneous expression of lymphoid markers and at least one myeloid-lineage-associated antigen. Our data confirm that immunophenotyping in ALL provides a solid basis for a biologically oriented and reliable classification of this heterogeneous disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075585     DOI: 10.3109/10428199409052679

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

Review 1.  Antibody Based Therapies in Acute Leukemia.

Authors:  Nirali N Shah
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

2.  Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

Authors:  Nitin Jain; Audrey V Lamb; Susan O'Brien; Farhad Ravandi; Marina Konopleva; Elias Jabbour; Zhuang Zuo; Jeffrey Jorgensen; Pei Lin; Sherry Pierce; Deborah Thomas; Michael Rytting; Gautam Borthakur; Tapan Kadia; Jorge Cortes; Hagop M Kantarjian; Joseph D Khoury
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113

3.  OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Authors:  Kathryn Evans; JianXin Duan; Tara Pritchard; Connor D Jones; Lisa McDermott; Zhaohui Gu; Cara E Toscan; Narimanne El-Zein; Chelsea Mayoh; Stephen W Erickson; Yuelong Guo; Fanying Meng; Donald Jung; Komal S Rathi; Kathryn G Roberts; Charles G Mullighan; Chi-Sheng Shia; Tillman Pearce; Beverly A Teicher; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2019-04-23       Impact factor: 13.801

4.  Myeloid Antigen Expression in Childhood Acute Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol.

Authors:  Eddy Supriyadi; Anjo J P Veerman; Ignatius Purwanto; Peter M Vd Ven; Jacqueline Cloos
Journal:  J Oncol       Date:  2012-11-26       Impact factor: 4.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.